A quick note on takeout odds for VKTX — and why the timing question matters more than the target question.
That Viking Therapeutics is a takeout candidate isn’t controversial. VK2735 is arguably the most advanced obesity asset still sitting outside Big Pharma’s walls — a dual GLP-1/GIP agonist in both subcutaneous and oral form, with the subcutaneous pro…
